|Bid||285.04 x 900|
|Ask||285.17 x 2200|
|Day's range||283.89 - 291.01|
|52-week range||187.16 - 311.88|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||14.73|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
When the Food and Drug Administration (FDA) rejects a key drug from a healthcare company, it can send the stock spiraling into a sell-off. In order for the FDA to be confident in a drug's effectiveness, it needs to have a large enough sample size to evaluate it. Unfortunately, in Eli Lilly's case, it simply didn't have enough data points for the agency to make a positive conclusion about the treatment and grant it accelerated approval.
Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.